Le azioni fluttuano di Volpara Health Technologies Limited è 190.067M 75.59%
Le fluttuazione delle azioni è la parte di azioni di una società che sono nelle mani di investitori pubblici rispetto a azioni bloccate.
Shares float represents the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock held by promoters, company officers, controlling-interest investors, or government. This number is sometimes seen as a better way of calculating market capitalization because it provides a more accurate reflection of what public investors consider the company to be worth. In this context, the float may refer to all the shares outstanding that can be publicly traded
The float is calculated by subtracting the locked-in shares from outstanding shares. Stocks with smaller floats tend to be more volatile than those with larger floats. In general, the large holdings of founding shareholders, corporate cross-holdings, and government holdings in partially privatized companies are excluded when calculating the size of a public float.
Volpara Health Technologies Limited provides breast imaging analytics and analysis products for the early detection of breast cancer in the medical device and practice management software industry worldwide. The company offers Volpara Analytics software, a cloud-based breast imaging analytics platform that delivers performance monitoring solutions; Volpara Live, which provides radiographers instant patient-based image quality feedback; Volpara Lung, a patient management software; and Volpara Patient Hub, a customizable mammography reporting and patient communications software. It also offers Volpara Risk, an integration with Patient Hub that uses Tyrer-Cuzick v8 Risk Evaluation Tool to calculate patients' risk of developing breast cancer; Volpara Scorecard, which displays patient breast density and risk insights essential for improved clinical decision-making and early detection; and Volpara Science, an AI-based software that powers Volpara software products. In addition, the company provides TruDensity, a Volpara clinical function; TruPGMI, a Volpara clinical function, which uses artificial intelligence to automatically and objectively assess the positioning of the patient and resulting image quality; TruPressure, a Volpara clinical function, which determines whether the compression pressure applied by the radiographer is in the sweet spot that yields quality images, minimal radiation exposure, and the least discomfort; and TruRadDose, a Volpara clinical function which analyses the radiation dose delivered to patients based on their breast density. Volpara Health Technologies Limited has a strategic relationship with RevealDx to enhance lung screening capabilities. The company was formerly known as Matakina Technology Ltd. and changed its name to Volpara Health Technologies Limited in October 2015. Volpara Health Technologies Limited was incorporated in 2009 and is headquartered in Wellington, New Zealand.